Experimental triple combo for tough breast cancer shows early promise but trial stops short
NCT ID NCT04095689
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tested a combination of chemotherapy (docetaxel), an immunotherapy drug (pembrolizumab), and a gene therapy (IL-12) in 8 women with triple negative breast cancer that had stopped responding to standard anthracycline treatment. The goal was to see if the combination could shrink or eliminate tumors. The study was terminated early, so the full safety and effectiveness picture is not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- docetaxel, pembrolizumab, and interleukin-12 gene therapy
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with hard-to-treat triple negative breast cancer that no longer responds to standard chemotherapy.
- What could go wrong
- This trial was terminated early with only 8 participants, so results are very limited. The combination of chemotherapy, immunotherapy, and gene therapy may cause significant side effects, and it is unclear if it works better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTHRACYCLINE-REFRACTORY TNBC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Houston Methodist Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- Could an oral chemo pill improve breast cancer treatment?
- Can a new nucleotide analogue boost cancer treatment?